Skip to main content
    I

    Instil Bio Inc. (TIL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.75
    -0.33 (-5.43%)

    Market Cap: $41.23M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Instil Bio Inc. (TIL) Financials: Revenue, Profit and Cash Flow

    Updated Nov 16, 2026. Financial statements from company filings, amounts in US dollars.

    Instil Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$71.37M, operating cash flow was -$36.62M and free cash flow was -$46.62M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$4.23M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $78.58M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$138.00KN/A100.0%-24379.7%-27346.4%
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$0$0$0$0$0$138.00K$0
    Cost of revenue$0$0$0$0$0$0$20.00K
    Gross profit$0$0$0$0$0$138.00K-$20.00K
    Research and development$34.74M$21.84M$39.60M$141.06M$107.25M$19.40M$4.03M
    Operating income-$78.58M-$73.54M-$159.17M-$226.46M-$155.56M-$33.64M-$6.58M
    Net income-$71.37M-$74.14M-$156.09M-$223.18M-$156.79M-$37.74M-$6.45M
    EBITDA-$77.83M-$72.79M-$154.99M-$221.03M-$154.08MN/A-$6.50M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$3.99M$0$0$0$7.67M
    Gross profit$0$0$0-$12.00K$0$0$0-$741.00K$0$0$0-$1.04M
    Operating income-$5.99M-$5.58M-$7.01M-$9.56M-$15.47M-$23.44M-$30.56M-$11.82M-$23.63M-$14.13M-$23.95M-$13.02M
    Net income-$4.23M-$4.30M-$4.20M-$8.19M-$13.59M-$21.39M-$28.20M-$11.89M-$23.02M-$14.92M-$24.30M-$12.93M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, total debt of $85.18M exceeded cash and equivalents by $78.54M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$204.51M$263.57M$325.63M$482.13M$609.98M$319.01M$9.48M
    Current assets$192.42M$124.47M$160.76M$269.38M$464.02M$246.14M$9.29M
    Cash and equivalents$6.64M$8.80M$9.20M$43.72M$37.59M$241.71M$8.89M
    Total liabilities$91.84M$94.13M$99.80M$118.52M$54.78M$26.64M$1.42M
    Short-term debt$372.00K$1.68M$1.75M$360.00K$1.34M$1.38MN/A
    Long-term debt$84.81M$84.19M$81.43M$72.35M$0N/AN/A
    Shareholder equity$112.67M$169.44M$225.83M$363.61M$555.20M-$39.60M$8.06M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$195.65M$197.71M$200.43M$203.52M$211.77M$230.99M$237.45M$263.57M$272.56M$294.32M$306.30M$325.63M
    Total liabilities$93.08M$90.33M$89.73M$89.66M$91.35M$99.32M$92.54M$94.13M$96.23M$99.30M$100.48M$99.80M
    Cash and equivalents$2.54M$5.54M$5.02M$6.64M$5.80M$7.69M$15.37M$8.80M$6.66M$6.78M$5.48M$9.20M
    Shareholder equity$102.56M$107.38M$110.70M$113.87M$120.42M$131.67M$144.91M$169.44M$176.33M$195.02M$205.83M$225.83M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$36.62M-$55.70M-$82.03M-$180.16M-$122.14M-$29.62M-$5.29M
    Capital expenditures$10.00M$10.00M$20.66M$84.59M$57.83M$50.82M$760.00K
    Free cash flow-$46.62M-$65.70M-$102.69M-$264.75M-$179.97M-$80.43M-$6.05M
    Investing cash flow$25.48M$53.97M$41.13M$114.54M-$474.40M-$51.12M-$760.00K
    Financing cash flow$7.29M$1.75M$8.08M$71.89M$393.16M$313.05M$14.95M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.40M-$4.64M-$1.34M-$7.08M-$10.56M-$14.79M-$4.20M-$10.56M-$20.13M-$10.61M-$14.39M-$13.38M
    Capital expendituresN/AN/A$0$0$0$0$0$0$0$0$0$58.00K
    Free cash flowN/AN/A-$1.34M-$7.08M-$10.56M-$14.79M-$4.20M-$10.56M-$20.13M-$10.61M-$14.39M-$13.44M
    Last 12 quarters

    Frequently Asked Questions About TIL

    What is Instil Bio's annual revenue?

    Instil Bio reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Instil Bio profitable?

    No. Instil Bio reported net income of -$71.37M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does TIL generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$36.62M minus capital expenditures of $10.00M produced free cash flow of -$46.62M.

    How much debt does Instil Bio have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $84.81M, short-term debt of $372.00K and cash and equivalents of $6.64M.